CXXC4 and acute myeloid leukemia: To determine whether CXXC4-ITD mutations similar to those identified in the mouse model are relevant for human disease, we analyzed whole-genome sequencing data from 591 AML patients generated at the Munich Leukemia Laboratory (MLL), complemented by targeted sequencing of 87 consecutive AML patients from the HOVON102 clinical trial.